
About Cara Therapeutics
Cara Therapeutics is a publicly listed company based in New York (United States) founded in 2004. Developer of therapeutics for pain relief and inflammatory diseases. Cara Therapeutics has raised $51 million across 5 funding rounds from investors including MVM Partners, Rho Capital Partners and Alta Partners. The company has 79 employees. Its chief executive, as recorded, is Christopher Posner. Cara Therapeutics offers products and services including IPF Therapy and Liver Cancer Treatment. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its competitors include Avidity Biosciences, Flexion Therapeutics and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.
Company details
Cara Therapeutics is developing cannabinoid and opioid receptor targeting therapeutics for pain relief and inflammatory diseases. Its proprietary technology DimerScreen identifies molecular structures that interact with the G-Protein-Coupled Receptors (GPCRS). Its lead candidate, CR845, is a peripheral kappa-opioid receptor agonist and is in Phase III trials for acute postoperative pain and pruritis. The company is also developing cannabinoid receptor agonists for pain relief.
- Headquarters New York, United States
- Employees 79
- Stage Public
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website caratherapeutics.com
- Social LinkedIn X
- Annual Revenue$4.33 M (USD)943as on Dec 31, 2024
- Net Profit-$70.87 M (USD)40as on Dec 31, 2024
- EBITDA-$58.38 M (USD)52as on Dec 31, 2024
- Total Equity Funding$51M (USD)
in 5 rounds
- Latest Funding Round$100K (USD), Post-IPO
Dec 2014
- InvestorsMVM Partners
& 7 more
- Employee Count79
Products & Services of Cara Therapeutics
Cara Therapeutics offers a comprehensive portfolio of products and services, including IPF Therapy and Liver Cancer Treatment.
Treatment for idiopathic pulmonary fibrosis through research trials.
Therapy targeting liver cancer in advanced stages.
Funding Insights of Cara Therapeutics
Cara Therapeutics has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 thousand completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51M
- Total Rounds 5
- Last Round Post-IPO β $100,003
- First Round $4.7M
(Dec 2005)
- Investors Count 8
All 5 funding rounds of Cara Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $100,003 | Post-IPO | β | β | β |
| Jul 2010 | $15M | Series D | β | Rho Capital Partners, SWIP | |
| Jul 2008 | $12.3M | Series C | β | β | |
| Nov 2006 | $19M | Series C | β | β | |
| Dec 2005 | $4.7M | Series B | β | β |
8 investors in total: 8 institutional.
Investors in Cara Therapeutics
Cara Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MVM Partners, Rho Capital Partners and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
| abvlp.com | ||||
| dpbioventures.com | ||||
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Esperante is focused on innovative life science investments. | esperante.com | Hoofddorp, Netherlands | ||
Offers investment management services focused on portfolio construction and risk assessment. | 1996 | swip.com | London, United Kingdom |
Investor details for Cara Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cara Therapeutics
25 people are tracked at Cara Therapeutics (17 in leadership, 4 in board & advisors, 4 in team); the tracked headcount is 79.
| Name | Role | Group |
|---|---|---|
Christopher Posner | CEO | Leadership |
Frédérique Menzaghi | Chief Scientific Officer, SVP Research & Development | Leadership |
Scott Terrillion | General Counsel, Secretary & Chief Compliance Officer | Leadership |
Rene Barron | Executive Director, HR | Leadership |
Ryan Maynard | Chief Financial Officer | Leadership |
Zachary Piracha | Associate Director, Drug Safety Pharmacovigilance | Leadership |
Jo Goncalves | Chief Medical Officer | Leadership |
Nilam Shah | Vice President, Clinical Research And Development | Leadership |
Diane Roth | Associate Director Clinical Project Management | Leadership |
Alia Jebara | Senior Medical Director | Leadership |
Michele Paz | Director Of Finance | Leadership |
Rick Makara | Vice President, Head Of Accounting And Controller | Leadership |
Stephen O’Connor | Vice President CMC Technical Operations | Leadership |
Tennador Sanderson | Sr. Director, Clinical Research & Development | Leadership |
Kristine Nograles | Vice President, Clinical Development | Leadership |
Andrew Albright | Executive Director, Alliance Management And Chief Of Staff | Leadership |
Ralph Vaccaro | Executive Director, Information Technology | Leadership |
Jeffrey L. Ives | Director | Board & advisors |
Lisa von Moltke | Director | Board & advisors |
Martin Vogelbaum | Chairman | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Cara Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cara Therapeutics
4 dated milestones of Cara Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Cara Therapeutics is founded.
- Funding First funding round of $4.7M.
- Funding Latest funding round, Post-IPO, of $100K.
- IPO Lists on the stock exchange (IPO).
Competitors of Cara Therapeutics
Cara Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Flexion Therapeutics and Sutro Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. |
Detailed competitors of Cara Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as Cara Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | 24 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cara Therapeutics
Complete news archive for Cara Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cara Therapeutics
Cara Therapeutics was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Cara Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Christopher Posner is the CEO of Cara Therapeutics, as recorded in our data.
Cara Therapeutics is a funded company, having raised a total of $51M across 5 funding rounds to date. The company's 1st funding round was a Series B of $4.7M, raised on Dec 2005.
Cara Therapeutics has 79 employees.
Annual revenue of Cara Therapeutics is $4.33M as on Dec 31, 2024.
Cara Therapeutics is developing cannabinoid and opioid receptor targeting therapeutics for pain relief and inflammatory diseases. Its proprietary technology DimerScreen identifies molecular structures that interact with the G-Protein-Coupled Receptors (GPCRS). Its lead candidate, CR845, is a peripheral kappa-opioid receptor agonist and is in Phase III trials for acute postoperative pain and pruritis. The company is also developing cannabinoid receptor agonists for pain relief.
Cara Therapeutics's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
Cara Therapeutics offers IPF Therapy and Liver Cancer Treatment.
Cara Therapeutics has 8 investors. Key investors include MVM Partners, Rho Capital Partners, Alta Partners, Connecticut Innovations, and SWIP.
